<SEC-DOCUMENT>0001615774-17-003423.txt : 20170630
<SEC-HEADER>0001615774-17-003423.hdr.sgml : 20170630
<ACCEPTANCE-DATETIME>20170630092901
ACCESSION NUMBER:		0001615774-17-003423
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170629
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170630
DATE AS OF CHANGE:		20170630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ATOSSA GENETICS INC
		CENTRAL INDEX KEY:			0001488039
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				264753208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35610
		FILM NUMBER:		17940535

	BUSINESS ADDRESS:	
		STREET 1:		107 SPRING STREET
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104
		BUSINESS PHONE:		206.588.0256

	MAIL ADDRESS:	
		STREET 1:		107 SPRING STREET
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s106725_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of Earliest Event Reported):
June 29, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Atossa Genetics Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Delaware </FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">001-35610 </FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">26-4753208</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of </FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 50%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">107 Spring Street</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Seattle, Washington</P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 49%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">98104</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices) </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (206)&nbsp;325-6086</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Not Applicable</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Former name or former address, if changed since
last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Written communications pursuant
to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 3.03 Material Modification to Rights of Security Holders.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 29, 2017, Atossa Genetics Inc. (the &ldquo;Company&rdquo;) offered to modify the rights (the &ldquo;Temporary
Modification&rdquo;) of the holders of the Warrants issued in the public offering the Company completed on April 3, 2017 (the &ldquo;Warrants&rdquo;).
In accordance with Sections 2 and 3 of the Warrants, the Temporary Modification included: (a) lowering the exercise price of the
Warrants to $0.26 per share, (b) setting the applicable &ldquo;VWAP&rdquo; (as defined in the Warrant) price at $0.52 per share,
and (c) allowing for temporary cashless exercise of the Warrants for all holders that accepted the Temporary Modification before
8:00 a.m. Eastern daylight time on June 30, 2017. Holders of Warrants to purchase a total of approximately 3.0 million shares of
Common Stock accepted the offer resulting in the cancellation of those warrants and the issuance by the Company of a total of approximately1.5
million shares of Common Stock (including shares held in abeyance in accordance with the following). The shares of Common Stock
are expected to be delivered on or about June 30, 2017 and are registered under the Securities Act of 1933, as amended. If delivery
of the shares of Common Stock pursuant to the foregoing would result in the holder exceeding the 4.99% &ldquo;Beneficial Ownership
Limitation&rdquo; (as defined in the Warrant) then the shares in excess of such 4.99% will be held in abeyance by the Company pending
further instruction from the holder. In connection with the Temporary Modification, the Company agreed to extend the &quot;Lock-up
Period&quot; contained in section 3.16.1 of the underwriting agreement between the Company and Aegis Capital Corp., dated March
28, 2017, by 45 days and the Company agreed not to enter into any further amendments to the Warrants during such extended Lock-up
Period without the prior written consent of each holder.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(d) Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A HREF="s106725_ex4-1.htm">4.1 Form of Reset Offer Letter from Atossa Genetics Inc. to holders of Warrants</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A HREF="s106725_ex99-1.htm">99.1 Press Release of the Company dated June 30, 2017</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Date: June 30, 2017</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Atossa Genetics Inc.&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Kyle Guse&nbsp;</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Kyle Guse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer, General Counsel and Secretary&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>s106725_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Exhibit 4.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">Re:</TD><TD STYLE="text-align: justify"><U>Reset Offer of Common Stock Purchase Warrants</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To Whom It May Concern:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are pleased to offer to you the opportunity
to reprice and exercise by means of cashless exercise all or any portion of the Common Stock Purchase Warrants of the Company issued
April 3, 2017 (the &ldquo;<U>Existing Warrants</U>&rdquo;) currently held by you (&ldquo;<U>Holder</U>&rdquo;), pursuant to the
authority reserved by us in Section 3(g) of the Existing Warrants. The Existing Warrants, and the shares underlying the Existing
Warrants (&ldquo;<U>Warrant Shares</U>&rdquo;) have all been registered for sale pursuant to a registration statement on Form S-1
(File No. 333-216031), the &ldquo;<U>Registration Statement</U>&rdquo;). The Registration Statement is currently effective and,
upon exercise of the Existing Warrants pursuant to this letter agreement, will be effective for the issuance of the Warrant Shares.
Capitalized terms not otherwise defined herein shall have the meanings set forth in the Warrant Agreement, dated as of April 3,
2017, by and among the Company and the Warrant Agent (the &ldquo;<U>Warrant Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In consideration for exercising the Existing
Warrants held by you (the &ldquo;<U>Warrant Exercise</U>&rdquo;), the number of which is set forth on the signature page hereto,
the Company hereby offers you a reduced exercise price of the Existing Warrants to $0.26 and the right to utilize cashless exercise
at a deemed market price (&ldquo;A&rdquo; in the cashless exercise formula) of $0.52, through and including any exercise made prior
to 8:00 a.m. Eastern Time on June 30, 2017, after which time, any unexercised Existing Warrants will revert automatically to their
existing terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Expressly subject to the paragraph immediately
following this paragraph below, Holder may accept this offer by signing this letter below, with such acceptance constituting Holder's
exercise of the Existing Warrants for an aggregate number of shares of Common Stock set forth on the Holder&rsquo;s signature page
hereto on or before 8:00 a.m. Eastern Time on June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If this Offer is accepted and this offer letter
is executed on or before 8:00 a.m. on June 30, 2017, then on or before 9:30 a.m. Eastern Time on June 30, 2017, the Company shall
file a Current Report on Form 8-K with the Commission disclosing the terms of this offer letter. The Company shall also file a
supplement to the prospectus to the Registration Statement registering the exercise of the Existing Warrants and disclosing the
terms of this offer and the reduced exercise price of the Existing Warrants on or before July 3, 2017. The Company represents that
as of the date hereof, there are 8,531,577 shares of Common Stock issued and outstanding. The Company represents, warrants and
covenants that, upon acceptance of this offer, the shares underlying the Existing Warrants shall be issued free of any legends
or restrictions on resale by Holder and all of the Warrant Shares shall be delivered electronically through the Depository Trust
Company within 1 business day of the date the Company receives this countersigned offer letter (or, if a Holder&rsquo;s exercise
would be in excess of the Beneficial Ownership Limitation, a Holder may accept this offer with respect to shares that would otherwise
be in excess of the Beneficial Ownership Limitation, however, such shares in excess of the Beneficial Ownership Limitation as noted
on the Holder&rsquo;s signature page hereto shall be held in abeyance, and not issued to the Holder until the date the Company
is notified by Holder from time to time that its ownership is less than the Beneficial Ownership Limitation, with such excess shares
being issued within 2 business days following each such notification). The terms of the Existing Warrants, including but not limited
to the obligations to deliver the Warrant Shares, shall otherwise remain in effect as if the acceptance of this offer were a formal
Notice of Exercise (including but not limited to any liquidated damages and compensation in the event of late delivery of the Warrant
Shares). The Company hereby agrees to extend the &quot;Lock-up Period&quot; contained in section 3.16.1 of the underwriting agreement
between the Company and Aegis Capital Corp., dated March 28, 2017, by 45 days and the Company agrees not to enter into any further
amendments to the Warrants during such extended Lock-up Period.&nbsp;The Company further agrees not to amend or waive the Lock-Up
Period without the prior written consent of the undersigned.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Holder represents, warrants and covenants
that the Holder has all right, title and interest in and to the Existing Warrants that are subject to the Warrant Exercise, free
and clear of any liens, claims and encumbrances and that the Holder has all authority to accept this offer and enter into the transactions
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To accept this offer, Holder must counter execute
this letter agreement and return the fully executed agreement to the Company at e-mail: kyle.guse@atossagenetics.com, attn.: Kyle
Guse on or before 8:00 a.m. on June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Please do not hesitate to call me if you have
any questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Sincerely yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ATOSSA GENETICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;Kyle Guse</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;CFO and General Counsel</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">HOLDER:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Existing Warrants being exercised:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Warrant Shares to be delivered by June 30, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Number of Warrant Shares being held in abeyance pending notification</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">From Holder regarding its Beneficial Ownership Limitation: ______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">DWAC delivery instructions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>s106725_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;<IMG SRC="pg1img1_ex99-1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Atossa Genetics Announces Warrant Exercises</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SEATTLE, June 30, 2017</B> &mdash; Atossa Genetics Inc. (NASDAQ:
ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast
conditions, today announced that holders of approximately 51% of the warrants issued in the public offering that closed on April
3, 2017 have exercised their warrants on a cashless basis. The Company offered all holders of the warrants the opportunity on or
before 8 a.m. Eastern time on June 30, 2017 to exercise the warrants on a cashless so that for each warrant the holder receives
one-half share of common stock. The warrant exercises are effective as of June 30, 2017 and result in the cancellation of approximately
3.0 million warrants and the issuance of approximately 1.5 million shares of registered common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&ldquo;The warrant exercises significantly improve Atossa&rsquo;s balance sheet and capital structure,&rdquo;
commented Kyle Guse, CFO and General Counsel of Atossa. &ldquo;As a result of the exercises, we have eliminated approximately 1.5
million shares from our overhang, reduced our derivative accounting liability and have increased our stockholders equity.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>About Atossa Genetics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Atossa Genetics Inc., is a clinical-stage pharmaceutical company
developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please
visit www.atossagenetics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Forward-looking statements in this press release, which Atossa undertakes
no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated
or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome
or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies,
the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles
resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, and other risks detailed from
time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports
on Form 10-K and 10-Q, each as amended and supplemented from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Atossa Genetics Company Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Atossa Genetics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Kyle Guse</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">CFO and General Counsel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(O) 800-351-3902</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">kyle.guse@atossagenetics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Investor Relations Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Scott Gordon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">CoreIR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">377 Oak Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Concourse 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Garden City, NY 11530</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Office: 516.222.2560</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">scottg@CoreIR.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Source: Atossa Genetics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pg1img1_ex99-1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg1img1_ex99-1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 8@$0 P$1  (1 0,1 ?_$ -,   (" @,! 0$
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MW(HG#H8%6N67:O&_6OS>;=V)?NV3TX@&XNHSW^$(XN:2V@E. :\QU=<3 _\
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MC1?B-77L6+Z4?,HN+9.Y*3DG;=A&QS!NJ[?2#YVJ5!JR9-4"G6<NG*QP(0A
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M Q@02=N""IT 1[.O0.O)'):VL+@6E[%=.%6QR-<1Z""O-JQAE+:SQC;/24A
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MMG!CD*X642,L!>[H'7D0 1B,?2O %SY<O-=KUW-J&L]1WV\WC/\ #;'-=T+
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M9:Q%&X5A8>=WH;C3UF@6*^$+71/7?QY8<1>LA:6S+B+S,]M.JGVNCNKL*2L
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MJ-J1F38RF5*(O$_BZ&B)EM69UX]81<B@]L\)"/?FG4<4SQ(&S24.J7L#U,0
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M+UHL3T,4Q3D.'V"')X$=R^EMS;6E];/M+R.*>RF86O8\-?'(QPQ#FD%KVN'
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M->OF<(T<LV;J6<-6ZBZ,<V=R"S=@V7>'("9#K*$2*8P"8P!U'C5?8T.>&N-
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MA!#)N6V$C((VD>!=8$, (_(<"%U?^5UOG_AYL/\ :"E_^9.%"NW_ (M/+O\
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M,HHHI8J:HHHH<1,=110]E,=10YA$1,(B(CZCPHNZ/-GY=6@-;N6V#0* ""Z
M &0 $% !P 7$IXN=\S)G*&O%B$1(8 #]H*7\1 0#_P"Y.,#%39YM?+L'"NYK
M;^0NOT"NFXUBW\)CF@0LHW,TDXBDU6+D6IS$.9L_803!H[;F.F8Z9C(N$C%$
M2B)1$/01#C7PIW1=6]_N;4;ZT<'VLU]</8[$<S'RO<TT-#B"#B 5FW!8)*,\
M>M*R;4MJO)';+SB;)%#J^<\[5_(N,;!;J^2+C+)6H6LA6':B:I'SE1H_/(%%
M1)NL0ASMNBGIZ@""LNMRV\NG6$<,L;Y(82UX::D$FO9V?.I+;L)R<C'8'A6N
M(+KF"#5SU4I6^P]6JS>TQT?C]K$V&'L[RQLW3E!!9B9M8"@#?M5.N4#]I1[>
M!70TGE:Z9YE9$_P2&DFA+J@BG?AFH1ZN:39OU W=AZ;2WTG:M!PJN6;]B)C)
MJ_-O\!WF['KS:?Q>#ITX%\2JRGLBZC4P*HF IF >Q0%.]4H>Y9;4=5M-3TDS
M3 -UKF8U],I&MK1_9S#(J4WE(U7O^WNI-AQIBIY'I9(KMSHF4Z7%3+T8Z#M4
MYCN=2FT*I,/OT;1I-HE.F110/:3<>V8XE* F!G$+'[>U&#3-3;<7(/P[FN8X
MC$@.%*CT+.\=;+Y<ODGB*I$U3S)0YN96*7,TKDF*80%)QA'Q=?=.90(6T,I2
M19Y D9.?219Q98T%45$E3++G0 G8("N&>PMH6RR?$Q/8/<#"2Y]3A44'* ,3
M7T"JQSR;ZNW3<'37*&%L<2,<PR \5K5LIB4RL#:&F+#2; PL;& EG1@$C1G-
M"Q,A[I@%--0Y#'^X!AX'$*>W]0BTO5([N<$PBK74S <"*CT5JH8;.T+.7D Q
M!JMKV3 .2L,S%9R_B+)6?KADB)C86L8VC\3)&7FXVCS;63>(W^7LTJ?V(P\3
M[K?Y414<'1_)X&IP65T^:ST6YN;TS1RL=$]D;6$DO+\BX4'* ,^;&N54[.>D
M0AX*7E!82DJ$;&/7GTV%9FDIF0^6;**_)QC$ITSO9!SV=B2?<43J" =0Z]>-
M5-C>9X;4"IS. 'I[E5@U6UDVOP?-:I9WLVON:,D5C$>;]B6V1->+C'0RLGBQ
MOF:ZR=@IFQ>!H)220:RTVQ@7I6\RW^87=(*>X5$I#*"<(XU[EL34;_3KMES9
MQSPQR2PQ%LK2:/Y&@.BD-, 3BW(=JM*665^F56;F"QDS*BTA'SXL1#1QW\\^
M$C-14K".BP.DHZDEQ^XFCW%$R@@ B'QY):\C;S2!M0*D8DX#TGL2-?%?HB=C
MC7$%VV>I.:X#+&N61\PS^+\:9)7CXW'5)D,DVN9EDKU4(6&;@:<G7T"\2*HX
M?O7?R+@3D333$ 'D0*#%6[<6KUN)8M/?$ZVGC8'O;4N=R #E).0KP %4RS?K
M72<VST]SSK[6)EO V?(U*6CZW)/55D8XL]&OV,Y$M94Z &4+%R#Z,(W<" &[
M4U1-T'IT&1Q6"T6^9IFJ0WT@YHXWU(XT.!IWT."6)GK&NQNY^CV"]'WFN^0\
M4Y.2F<+5[-ETN#2,9XMQU7,0.(P;)<*G=&<H[;WI6QI0A/HK2+*JXZN?]H!
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M@(JCV]>26N VK^2HSI6N'IKV*MWF+".VK^Y8&\A=2QIEN=SC ;=V*TS6NO\
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%'!"__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
